Bone marrow stem cells may cure eye disease

Scientists have completed a study using mice which showed that bone marrow stem cells can switch roles and produce keratocan, a natural protein involved in the growth of the cornea—the transparent, outer layer of the eyeball. This ability of marrow cells to "differentiate" into keratocan-producing cells might provide a means for treating abnormal corneal cell growth in people.

Winston Whei-Yang Kao, PhD, professor of ophthalmology, and Hongshan Liu, PhD, research scientist in the department of ophthalmology, will present their findings at the annual meeting of the Association for Research in Vision and Ophthalmology being held in Ft. Lauderdale, Fla., May 9 and10.

In the laboratory, the researchers induced corneal abnormalities that mimicked genetic eye mutations and then injected bone marrow stem cells into the corneas to see if they altered the mutations.

The study showed that after only one week, the abnormal corneas of animal models injected with bone marrow stem cells began to change shape and heal.

"We found that bone marrow stem cells can contribute to the formation of connective tissues," Kao said. "If we can change the function of non-corneal bone marrow stem cells by introducing them into human corneas, we can possibly repair the loss of visual sharpness caused by mutations."

Kao and his coworkers are now planning a clinical trial. If the trial succeeds, Kao said, the procedure could help prevent blindness in future generations who suffer from genetic corneal diseases.

He added that cornea transplants have been successful to some degree but do not always eliminate the problem.

"When the donor cells disappear after a few years, the corneal disease often reoccurs," he said. "However, if we can place the stem cells inside the cornea, they will repair the lost function of the mutated gene, and stem cells can presumably renew themselves and maintain effective treatment longer, if not forever."

Source: University of Cincinnati

Time of day influences yield for pharmacologically stimulated stem cell mobilization
A new study uncovers a previously unrecognized, species-specific impact of circadian rhythms on the production of mobilized stem cells. The research, published by Cell Press in the October 9th issue of the journal Cell Stem Cell, suggests that when it comes to collecting human stem cells for clinical transplantation, picking the right time of day to harvest cells may result in a greater yield.
Scientists pinpoint key proteins in blood stem cell replication
A family of cancer-fighting molecules helps blood stem cells in mice decide when and how to divide, say researchers at the Stanford University School of Medicine. Blocking the molecules' function spurs the normally resting cells to begin proliferating strangely - making too much of one kind of cell and not enough of another. Many types of human blood cancers involve a similar disruption in the expression of that same family of molecules.
Can stem cells heal damaged hearts? No easy answers, but some signs of hope
Recent studies indicate that infusing hearts with stem cells taken from bone marrow could improve cardiac function after myocardial infarction (tissue damage that results from a heart attack). But in a recent systematic review, Cochrane Researchers concluded that more clinical trials are needed to assess the effectiveness of stem cell therapies for heart patients, as well as studies to establish how these treatments work.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
New leukemia signal could point way to better treatment
Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.
Engineered stem cells carry promising ALS therapy
(PhysOrg.com) -- Using adult stem cells from bone marrow as "Trojan horses"to deliver a nurturing growth factor to atrophied muscles, Wisconsin scientists have successfully slowed the progression of ALS in rats.
Embryonic stem cells might help reduce transplantation rejection
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs.
NC State first university in nation to offer canine bone marrow transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.

Bone marrow stem cells may cure eye disease

Related stories:

News discussion: